Abraham Ceesay - 04 Sep 2025 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role
Director
Signature
/s/ Kristen Williams, Attorney-in-Fact
Issuer symbol
PCRX
Transactions as of
04 Sep 2025
Transactions value $
-$64,005
Form type
4
Filing time
08 Sep 2025, 17:37:14 UTC
Previous filing
13 Jun 2025
Next filing
19 Sep 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ceesay Abraham Director C/O PACIRA BIOSCIENCES, INC., 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE /s/ Kristen Williams, Attorney-in-Fact 08 Sep 2025 0001722140

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PCRX Common Stock Sale -$64K -2.35K -20.66% $27.19 9.04K 04 Sep 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.